Cardiothoracic Surgery

You are here

Transcatheter Valve Replacement (TAVR, TMVR)

Weill Cornell Medicine|NewYork-Presbyterian is a leader in the development of percutaneous transcatheter valve replacement technology (TAVR and TMVR). Our team plays a leading role in the clinical trials assessing the latest percutaneous mitral and aortic valve replacement approaches, giving us more experience than most centers in these emerging new techniques. We have achieved superior outcomes using these innovative approaches, which make valve replacement possible for many patients who otherwise would not tolerate conventional heart surgery.

Patients who come to us receive comprehensive care from a team with exceptional experience in the repair and replacement of heart valves. A patient can meet with cardiologists, surgeons and other healthcare professionals in one day, in one convenient location, to obtain a diagnosis and recommendations for a treatment plan.

Weill Cornell Medicine|NewYork-Presbyterian physicians have participated as investigators in two pivotal clinical trials which established the effectiveness of percutaneous (transcatheter) valve surgery:

  • The PARTNER Trial, which in 2011 demonstrated that transcatheter aortic valve implantation (TAVI) was as effective as conventional open-heart surgery for reducing mortality among high-risk patients with aortic stenosis. In 2010, PARTNER Trial investigators reported that patients who were not candidates for surgery fared much better with TAVI than patients who were treated medically.
  • The EVEREST II trial, which evaluated the percutaneous implantation of a clip that grasps and approximates the edges of the mitral valve leaflets. The percutaneous approach was associated with superior safety and similar improvements in clinical outcomes compared with conventional surgery.

Weill Cornell continues to evaluate transcatheter approaches for mitral and aortic valve replacement by participating and enrolling patients in the Everest II, Partner II and Partner III trials.

Carolyn Levine was diagnosed with aortic stenosis, a narrowing or calcification of one of the critical valves of the heart. This type of diagnosis, if untreated, usually leads to death within two years. Because of age and prior surgeries, Carolyn was considered too high risk for open-heart surgery. But Weill Cornell doctors used a new, minimally invasive procedure called TAVR, Transcatheter Aortic Valve Replacement, which has extended and improved her quality of life.

 

Interview with Dr. Arash Salemi regarding New Aortic Stenosis Treatments at Valves in the Heart of the Big Apple 2012.

 

Other Resources

Patient guide to TAVR

Trascatheter Aortic Valve Replacement (TAVR)

Our Surgeons

(212) 746-5873

Weill Cornell Medicine Cardiothoracic Surgery 525 East 68th Street
Box 110
Suite M 404
New York, NY 10065 Directions
Phone: (212) 746-5166